bioRxiv Science⌕ Search

Biology subjects

Lawrie, C. H.

Publications and source records attributed to Lawrie, C. H..

2 recordsLinked to original sources

POZ Domain Transcription Factor Kaiso is a Downstream Effector of STAT1 for Multiple Myeloma Cell Survival and is also essential for Anoikis Resistance of Metastatic Solid Tumors

Role of the transcription factor STAT1 in cancer cell survival has remained unclear. Here we document an oncogenic role for STAT1 in Multiple Myeloma (MM), wherein STAT1 regulates Kaiso expression, represses bmf and is essential for MM cell survival. Moreover, STAT1 is constitutively phosphorylated in MM cell lines and patient derived primary MM cells and STAT1-depletion resulted in reduced Kaiso levels. Importantly, expression of exogenous Kaiso rescued STAT1-depleted MM cells from apoptosis by reversing elevated BMF levels. Further, several MM cell lines harboring diverse oncogenic mutations rely on Kaiso for their survival revealing an oncogenic addiction to Kaiso in MM. Mechanistically, Kaiso interacts with and recruits HDAC1 to pro-apoptotic gene bmf promoter to maintain repressive state. In line with this, depletion of Kaiso or HDAC1 results in elevated BMF levels and apoptosis of MM cells. Kaiso is abundantly expressed in several MM cell lines and patient derived primary MM cells. Interestingly, Kaiso interacting partner p120-catenin levels are very low/undetectable in MM indicating that Kaiso function in MM is p120-independent. While previous reports suggested anoikis promoting role for Kaiso in breast cancer, we show here that bmf repression by Kaiso is central to anoikis-resistance of metastatic solid tumors. Collectively, our data indicate that Kaiso is a downstream effector for STAT1 in MM cell survival and that Kaiso mediated bmf repression is central to MM cell survival and anoikis resistance of metastatic solid tumors. Targetting Kaiso-mediated bmf repression would enable us to develop common drug for MM and metastasis of solid tumors.

cancer biology↗

Myeloid derived Oncostatin M reprogrammes cancer-associated fibroblasts and tumour cells promoting breast cancer progression

Cancer cells are constantly communicating with the surrounding tumour microenvironment (TME) and they hijack physiological cell interactions to overcome immune system surveillance and promote cancer progression1,2. However, the contribution of stromal cells to the reprogramming of the TME is not well understood. In this study we provide unprecedented evidence of the role of the cytokine Oncostatin M (OSM) as central node for multicellular interactions between immune and non-immune stroma and the epithelial compartment. We show that stromal expression of the OSM:Oncostatin M Receptor (OSMR) axis plays a key role in breast cancer progression. OSMR deletion in a multistage breast cancer model delays tumour onset, tumour growth and reduces metastatic burden. We ascribed causality to the stromal function of OSM axis by demonstrating reduced tumour burden of syngeneic tumours implanted in mice. Single-cell and bioinformatic analysis of murine and human breast tumours revealed that the expression of OSM signalling components is compartmentalized in the tumour stroma. OSM expression is restricted to myeloid cells, whereas OSMR expression is detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprograms fibroblasts to a more contractile and pro-tumorigenic phenotype, elicits the secretion of VEGF and pro-inflammatory chemokines (e.g. CXCL1 and CXCL16), leading to increased neutrophil and macrophage recruitment. In summary, our work sheds light on the mechanism of immune regulation by the tumour microenvironment, and supports that targeting OSM:OSMR interactions is a potential therapeutic strategy to inhibit tumour-promoting inflammation and breast cancer progression.

cancer biology↗